BCL2L11 and non-small cell lung carcinoma: Interestingly, vorinostat, an FDA-approved histone deacetylase inhibitor, corrected aberrant BIM splicing and counteracted EGFR-TKI resistance in NSCLC cell lines harboring the BIM deletion polymorphism (Nakagawa et al., 2013).